Metabolomics Core

代谢组学核心

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT – CORE B Allogenic hematopoietic stem cell transplant (allo-HCT) can provide a cure for chronic infections, genetic diseases, or cancers of the blood. However, its therapeutic utility is limited by associated toxicities resulting from graft versus host disease (GVHD). Among the most prominent morbidities of GVHD is damage to the gastrointestinal tract. Recent results from our groups have revealed that the severity of GVHD is impacted by the nature and metabolic properties of the gut microbiome. Further, we found that promotion of microbial communities that facilitate the metabolism of starch into butyrate and reprogram bile acid metabolism of the host ameliorate or even prevent GVDH following BMT. The measure and quantitation of metabolism is essential to address the associated experimental aims across the research proposals. The purpose of the Metabolomics core is to support the research projects that build on these studies to detect and quantify metabolites from these pathways in stool from mice, bacterial populations, human epithelial cells, and longitudinal stool samples of patients in the associated clinical trial. Further, this core will also provide global insights into host and microbiome metabolism using stable isotope tracing technologies and untargeted metabolome-wide profiling. By centralizing the development, maintenance, and implementation of metabolomics methods, this core will provide state-of-the-art capabilities to facilitate data collection and analysis while ensuring consistency across projects.
项目总结/摘要-核心B 异基因造血干细胞移植(allo-HCT)可以治疗慢性感染、遗传性疾病和其他疾病。 疾病或血液癌症。然而,其治疗效用受到相关毒性的限制 由移植物抗宿主病(GVHD)引起。GVHD最突出的发病率之一是 对胃肠道的损害。我们小组最近的结果显示, GVHD受肠道微生物组的性质和代谢特性的影响。此外,我们发现, 促进微生物群落,促进淀粉代谢为丁酸和重编程 宿主的胆汁酸代谢改善甚至预防BMT后的GVDH。的措施和 代谢的定量对于解决跨学科的相关实验目标至关重要。 研究提案。代谢组学核心的目的是支持研究项目, 在这些研究的基础上,检测和定量小鼠粪便中这些途径的代谢物,细菌 在相关的临床试验中,患者的群体、人上皮细胞和纵向粪便样品被检测。 审判此外,该核心还将使用稳定的微生物代谢提供对宿主和微生物组代谢的全球见解。 同位素示踪技术和非靶向代谢组范围分析。通过集中开发, 维护和代谢组学方法的实施,这一核心将提供最先进的 能力,以促进数据收集和分析,同时确保跨项目的一致性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Costas Andreas Lyssiotis其他文献

Costas Andreas Lyssiotis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Costas Andreas Lyssiotis', 18)}}的其他基金

Stromal metabolism promotes therapeutic resistance in pancreatic cancer
基质代谢促进胰腺癌的治疗抵抗
  • 批准号:
    10368125
  • 财政年份:
    2020
  • 资助金额:
    $ 25.62万
  • 项目类别:
Metabolomics Core
代谢组学核心
  • 批准号:
    10241902
  • 财政年份:
    2020
  • 资助金额:
    $ 25.62万
  • 项目类别:
Targeting metabolic stress to induce pancreatic tumor cell death
针对代谢应激诱导胰腺肿瘤细胞死亡
  • 批准号:
    10408692
  • 财政年份:
    2020
  • 资助金额:
    $ 25.62万
  • 项目类别:
Stromal metabolism promotes therapeutic resistance in pancreatic cancer
基质代谢促进胰腺癌的治疗抵抗
  • 批准号:
    10116342
  • 财政年份:
    2020
  • 资助金额:
    $ 25.62万
  • 项目类别:
Stromal metabolism promotes therapeutic resistance in pancreatic cancer
基质代谢促进胰腺癌的治疗抵抗
  • 批准号:
    10596979
  • 财政年份:
    2020
  • 资助金额:
    $ 25.62万
  • 项目类别:
Targeting metabolic stress to induce pancreatic tumor cell death
针对代谢应激诱导胰腺肿瘤细胞死亡
  • 批准号:
    10656461
  • 财政年份:
    2020
  • 资助金额:
    $ 25.62万
  • 项目类别:
Metabolomics Core
代谢组学核心
  • 批准号:
    10650306
  • 财政年份:
    2020
  • 资助金额:
    $ 25.62万
  • 项目类别:
Intratumoral Metabolic Crosstalk Promotes Therapeutic Resistance in Pancreatic Cancer
瘤内代谢串扰促进胰腺癌的治疗耐药
  • 批准号:
    9887919
  • 财政年份:
    2019
  • 资助金额:
    $ 25.62万
  • 项目类别:
Intratumoral Metabolic Crosstalk Promotes Therapeutic Resistance in Pancreatic Cancer
瘤内代谢串扰促进胰腺癌的治疗耐药
  • 批准号:
    10543534
  • 财政年份:
    2019
  • 资助金额:
    $ 25.62万
  • 项目类别:
Intratumoral Metabolic Crosstalk Promotes Therapeutic Resistance in Pancreatic Cancer
瘤内代谢串扰促进胰腺癌的治疗耐药
  • 批准号:
    10305594
  • 财政年份:
    2019
  • 资助金额:
    $ 25.62万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 25.62万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了